Evogene completes the sale of Lavie Bio to ICL

Evogene (TASE: EVGN), an Israeli computational biology company, announced Tuesday that it has finalized the sale of key activities of its ag-biologicals subsidiary Lavie Bio to global specialty minerals firm ICL Group (TASE: ICL).

Under the deal, originally disclosed in April 2025, ICL acquired Lavie Bio’s proprietary Biology Driven Design (BDD) technology platform, microbial bank, late-stage development pipeline, and commercial product portfolio. A portion of Lavie Bio’s staff will also join ICL. In addition, Evogene divested its MicroBoost AI for Agriculture platform, which accelerates microbial product discovery through artificial intelligence, for separate consideration.

The transaction does not include Lavie Bio’s existing commercial partnerships and strategic agreements, which remain under its ownership and may generate future revenue.

Evogene, which uses artificial intelligence and big data to develop life science products, will continue operations through its other subsidiaries, including AgPlenus (agrochemicals) and Biomica (human microbiome therapeutics).

Financial terms of the transaction were not disclosed.